CN102076359A - 疫苗组合物和方法 - Google Patents

疫苗组合物和方法 Download PDF

Info

Publication number
CN102076359A
CN102076359A CN2009801254981A CN200980125498A CN102076359A CN 102076359 A CN102076359 A CN 102076359A CN 2009801254981 A CN2009801254981 A CN 2009801254981A CN 200980125498 A CN200980125498 A CN 200980125498A CN 102076359 A CN102076359 A CN 102076359A
Authority
CN
China
Prior art keywords
cell
antigens
compositions
activated
host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801254981A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·哈-诺伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovative Therapies Ltd
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Priority to CN201810586541.5A priority Critical patent/CN108743937B/zh
Publication of CN102076359A publication Critical patent/CN102076359A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4262—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2009801254981A 2008-05-02 2009-05-04 疫苗组合物和方法 Pending CN102076359A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810586541.5A CN108743937B (zh) 2008-05-02 2009-05-04 疫苗组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4999008P 2008-05-02 2008-05-02
US61/049,990 2008-05-02
US5029408P 2008-05-05 2008-05-05
US61/050,294 2008-05-05
PCT/US2009/042673 WO2009135199A2 (en) 2008-05-02 2009-05-04 Vaccine compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810586541.5A Division CN108743937B (zh) 2008-05-02 2009-05-04 疫苗组合物和方法

Publications (1)

Publication Number Publication Date
CN102076359A true CN102076359A (zh) 2011-05-25

Family

ID=41255892

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801254981A Pending CN102076359A (zh) 2008-05-02 2009-05-04 疫苗组合物和方法
CN201810586541.5A Active CN108743937B (zh) 2008-05-02 2009-05-04 疫苗组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810586541.5A Active CN108743937B (zh) 2008-05-02 2009-05-04 疫苗组合物和方法

Country Status (9)

Country Link
US (3) US20120128656A1 (enExample)
EP (1) EP2285405A4 (enExample)
JP (2) JP5709264B2 (enExample)
KR (1) KR101689210B1 (enExample)
CN (2) CN102076359A (enExample)
AU (1) AU2009242471B2 (enExample)
CA (1) CA2726007C (enExample)
IL (1) IL209027A (enExample)
WO (1) WO2009135199A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103911341A (zh) * 2014-01-26 2014-07-09 山东迪博生物技术有限公司 Th1细胞亚群的制备方法及其在制备抗肿瘤细胞制剂中的应用
WO2015027915A1 (zh) * 2013-09-02 2015-03-05 北京中康万达医药科技有限公司 体内个体化系统免疫治疗方法和装置
CN104630145A (zh) * 2015-01-12 2015-05-20 杨世成 一种抗肿瘤t细胞、其制备方法和抗肿瘤药物
CN104830794A (zh) * 2015-05-05 2015-08-12 杨光华 基于hpve7抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
WO2025113111A1 (zh) * 2023-11-28 2025-06-05 苏州尔生生物医药有限公司 一种抗原组分的提取方法及包含其的递送粒子和应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
KR102117350B1 (ko) * 2010-04-13 2020-06-02 이뮤노베이티브 테라피스, 엘티디. 조절 t 세포들의 저해를 위한 방법 및 조성물
BR112013028285A2 (pt) * 2011-05-03 2017-01-10 Immunovative Therapies Ltd indução de il-12 usando imunoterapia
US10272143B2 (en) 2014-01-08 2019-04-30 Immunovative Therapies Ltd. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
AU2017233035B2 (en) * 2016-03-16 2021-08-05 Neximmune, Inc. Production of antigen-specific T-cells
KR20170127324A (ko) * 2016-05-11 2017-11-21 (주)제이티 반도체소자 캐리어, 이의 제조방법 및 이를 포함하는 소자핸들러
IL300809A (en) * 2020-09-02 2023-04-01 Yztherapeutic Performance Ltd Cellular preparation for the treatment of diseases and method of use
CA3243354A1 (en) * 2022-02-03 2023-08-10 Microvax Llc A mRNA VACCINE DESIGN USING MULTIPLE INTERACTING IMMUNO-STIMULATORY PATHWAYS, FOR CANCER AND INFECTIOUS DISEASES
US20250319132A1 (en) * 2024-04-16 2025-10-16 Mirror Biologics, Inc. Methods and compositions for improving the immune response against viral pathogens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040228848A1 (en) * 2003-05-13 2004-11-18 Michael Har-Noy Allogeneic cell therapy: mirror effect
WO2007120128A1 (en) * 2006-04-13 2007-10-25 Immunovative Therapies, Ltd. Allogeneic cell therapy for treatment of opportunistic infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US6875849B2 (en) * 2001-05-01 2005-04-05 Arizona Board Of Regents Of Behalf Of The University Of Arizona Methods of recovering chaperone proteins and complexes thereof
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20040202663A1 (en) * 2003-01-28 2004-10-14 Shanghai Sunway Biotech Co., Ltd. Therapy for primary and metastatic cancers
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7678572B2 (en) 2004-02-26 2010-03-16 Immunovative Therapies, Ltd. Methods for preparing T-cells for cell therapy
EP1896570A2 (en) * 2005-05-10 2008-03-12 Avaris AB Cellular vaccine and use thereof
US7553661B2 (en) * 2005-05-31 2009-06-30 Mcgill University Stromal antigen-presenting cells and use thereof
EP2091334A4 (en) * 2006-10-31 2010-02-03 Hasumi Internat Res Foundation TUMOR TREATMENT BY INJECTION OF DENDRITIC CELLS AND CORRESPONDING VACCINE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040228848A1 (en) * 2003-05-13 2004-11-18 Michael Har-Noy Allogeneic cell therapy: mirror effect
WO2007120128A1 (en) * 2006-04-13 2007-10-25 Immunovative Therapies, Ltd. Allogeneic cell therapy for treatment of opportunistic infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAR-NOY M. ET AL.: "The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?", 《MEDICAL HYPOTHESES》 *
WOODLAND DAVID L.: "Jump-starting the immune system: prime–boosting comes of age", 《TRENDS IN IMMUNOLOGY》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027915A1 (zh) * 2013-09-02 2015-03-05 北京中康万达医药科技有限公司 体内个体化系统免疫治疗方法和装置
US10980859B2 (en) 2013-09-02 2021-04-20 Hangzhou Converd Co., Ltd. In vivo individualized systemic immunotherapeutic method and device
CN103911341A (zh) * 2014-01-26 2014-07-09 山东迪博生物技术有限公司 Th1细胞亚群的制备方法及其在制备抗肿瘤细胞制剂中的应用
CN103911341B (zh) * 2014-01-26 2016-04-13 山东迪博生物科技股份有限公司 Th1细胞亚群的制备方法及其在制备抗肿瘤细胞制剂中的应用
CN104630145A (zh) * 2015-01-12 2015-05-20 杨世成 一种抗肿瘤t细胞、其制备方法和抗肿瘤药物
CN104830794A (zh) * 2015-05-05 2015-08-12 杨光华 基于hpve7抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
WO2025113111A1 (zh) * 2023-11-28 2025-06-05 苏州尔生生物医药有限公司 一种抗原组分的提取方法及包含其的递送粒子和应用

Also Published As

Publication number Publication date
AU2009242471A1 (en) 2009-11-05
JP2014098035A (ja) 2014-05-29
AU2009242471B2 (en) 2015-06-11
CA2726007A1 (en) 2009-11-05
CA2726007C (en) 2019-04-09
WO2009135199A2 (en) 2009-11-05
US20200261509A1 (en) 2020-08-20
US20120128656A1 (en) 2012-05-24
CN108743937B (zh) 2022-08-30
JP5709264B2 (ja) 2015-04-30
EP2285405A4 (en) 2012-09-19
KR20110002496A (ko) 2011-01-07
IL209027A0 (en) 2011-01-31
IL209027A (en) 2017-11-30
US20190105350A1 (en) 2019-04-11
EP2285405A2 (en) 2011-02-23
KR101689210B1 (ko) 2016-12-23
US12233091B2 (en) 2025-02-25
WO2009135199A3 (en) 2010-03-04
CN108743937A (zh) 2018-11-06
US10751372B2 (en) 2020-08-25
JP2011519869A (ja) 2011-07-14

Similar Documents

Publication Publication Date Title
US12233091B2 (en) Vaccine compositions and methods
Bhardwaj Processing and presentation of antigens by dendritic cells: implications for vaccines
JP2016041725A (ja) ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
EP2547360A1 (en) System and method of preparing and storing activated mature dendritic cells
US11833173B2 (en) Th1 vaccination priming for active immunotherapy
JP2014521657A (ja) 膵臓がんに対する樹状細胞（ｄｃ）ワクチン療法
Singh et al. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy
HK1158090A (en) Vaccine compositions and methods
HK40000110A (en) Vaccine compositions and methods
HK40000110B (en) Vaccine compositions and methods
HK1211230B (en) Th1 vaccination priming for active immunotheraphy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1158090

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20110525

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1158090

Country of ref document: HK